Takotsubo Syndrome: A Contemporary Review of Pathophysiology, Management, Controversies, and Emerging Directions

Abstract Purpose of Review Once considered benign and self-limiting, Takotsubo syndrome (TTS) is now recognized as an acute cardiac syndrome associated with substantial in-hospital and long-term morbidity and mortality. This review synthesizes contemporary advances in TTS pathophysiology, management, outcomes, and ongoing controversies, with an emphasis on the emerging mechanistic and therapeutic landscape. Recent Findings Our mechanistic understanding of TTS has been recently refined by invasive and noninvasive studies associating coronary microvasculature functionality with disease onset and recovery, neuroimaging implicating heightened amygdala activity and altered limbic connectivity as predisposing neurobiological features, and cardiac and serologic inflammatory markers suggesting both upstream and downstream pathologic influences from immune activation. Contemporary registry data suggest that inpatient mortality and long-term outcomes in TTS patients may be comparable to those in ACS. Furthermore, small case-control data suggest that more than 80% of survivors report persistent symptoms. Data on aspirin and statin use in the absence of CAD suggest limited benefit, while β-blocker and RAASi signals remain discordant across modern registries. The first mechanism-targeted randomized trials, including BROKEN-SWEDEHEART (adenosine/dipyridamole and apixaban), CIT (cyclosporine A), and BREAKOUT (CBT and structured exercise), are now reporting or recruiting, and will provide much-needed evidence to guide future management. Summary TTS is a complex, multifactorial acute cardiac syndrome with long-term consequences, at an inflection point of mechanistic and therapeutic discovery. In the absence of randomized controlled trial data, management remains individualized and guided by expert statements. Continued international, multidisciplinary collaboration spanning cardiology, neurology, psychiatry, endocrinology, and basic science will be essential to translate emerging insights into meaningful improvements in patient outcomes.

Authors

Institutions

Publication Details

Journal
Current Cardiovascular Risk Reports
Published
2026-11-17
DOI
https://doi.org/10.1007/s12170-026-00805-z
Primary Topic
Takotsubo Cardiomyopathy and Associated Phenomena
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Takotsubo Syndrome: A Contemporary Review of Pathophysiology, Management, Controversies, and Emerging Directions

Paul Marano, Trinh K. Do, Janet Wei, Alexander Y. Lee
3 links
Current Cardiovascular Risk Reports
Takotsubo Cardiomyopathy and Associated Phenomena
article

Takotsubo Syndrome: A Contemporary Review of Pathophysiology, Management, Controversies, and Emerging Directions

Paul Marano, Trinh K. Do, Janet Wei, Alexander Y. Lee
article en

Abstract

Abstract Purpose of Review Once considered benign and self-limiting, Takotsubo syndrome (TTS) is now recognized as an acute cardiac syndrome associated with substantial in-hospital and long-term morbidity and mortality. This review synthesizes contemporary advances in TTS pathophysiology, management, outcomes, and ongoing controversies, with an emphasis on the emerging mechanistic and therapeutic landscape. Recent Findings Our mechanistic understanding of TTS has been recently refined by invasive and noninvasive studies associating coronary microvasculature functionality with disease onset and recovery, neuroimaging implicating heightened amygdala activity and altered limbic connectivity as predisposing neurobiological features, and cardiac and serologic inflammatory markers suggesting both upstream and downstream pathologic influences from immune activation. Contemporary registry data suggest that inpatient mortality and long-term outcomes in TTS patients may be comparable to those in ACS. Furthermore, small case-control data suggest that more than 80% of survivors report persistent symptoms. Data on aspirin and statin use in the absence of CAD suggest limited benefit, while β-blocker and RAASi signals remain discordant across modern registries. The first mechanism-targeted randomized trials, including BROKEN-SWEDEHEART (adenosine/dipyridamole and apixaban), CIT (cyclosporine A), and BREAKOUT (CBT and structured exercise), are now reporting or recruiting, and will provide much-needed evidence to guide future management. Summary TTS is a complex, multifactorial acute cardiac syndrome with long-term consequences, at an inflection point of mechanistic and therapeutic discovery. In the absence of randomized controlled trial data, management remains individualized and guided by expert statements. Continued international, multidisciplinary collaboration spanning cardiology, neurology, psychiatry, endocrinology, and basic science will be essential to translate emerging insights into meaningful improvements in patient outcomes.

Current Cardiovascular Risk ReportsVol. 20(1)
Cedars-Sinai Medical Center (US), Cedars-Sinai Smidt Heart Institute (US)
Cedars-Sinai Medical Center
Good health and well-being
Takotsubo Cardiomyopathy and Associated Phenomena
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon